Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Prostate and Urologic Cancer Research Group

Publications

View All  |  2014-2010  |  2009-2006

  • Coming soon.
  • Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate. 2013 Feb 15;73(3):328-35.
    [ PubMed Abstract ]
  • Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013 Aug 7;105(15):1132-41.
    [ PubMed Abstract ]
  • Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int. 2013 Jun;111(8):1269-80.
    [ PubMed Abstract ]
  • Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res (Phila). 2013 Feb;6(2):91-9.
    [ PubMed Abstract ]
  • Parnes HL, House MG, Tangrea JA. Prostate cancer prevention: strategies for agent development. Curr Opin Oncol. 2013 May;25(3):242-51
    [ PubMed Abstract ]
  • Pinsky PF, Parnes HL, Andriole G. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. BJU Int. 2013 Jul 19.
    [ PubMed Abstract ]
  • Stamatakis L, Siddiqui MM, Nix JW, Logan J, Rais-Bahrami S, Walton-Diaz A, Hoang AN, Vourganti S, Truong H, Shuch B, Parnes HL, Turkbey B, Choyke PL, Wood BJ, Simon RM, Pinto PA. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer. 2013 Sep 15;119(18):3359-66.
    [ PubMed Abstract ]
  • Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013 Aug 15;369(7):603-10.
    [ PubMed Abstract ]
  • Curiel-Lewandowski C, Swetter S, Einspahr JG, Hsu CH, Nagle R, Sagerman P, Tangrea J, Parnes H, Alberts DS, Chow HH. Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. Cancer. 2012, in press.
  • Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby J, Hohl R, Bailey H. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila). 2012 Jan 31. [Epub ahead of print ].
    [ PubMed Abstract ]
  • Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, Sokoloff MH, Gretzer MB, Chow HH. Randomized, double-blind, placebo-controlled trial of Polyphenon E in prostate cancer before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila). 2012 Feb: 5(2); 290-8.
    [ PubMed Abstract - in process ]
  • Kidd LR, Hein DW, Woodson K, Taylor PR, Albanes D, Virtamo J, Tangrea JA. Lack of association of the N-acetyltransferase NAT1*10 allele with prostate cancer incidence, grade or stage among smokers in Finland. Biochem Genet. 2011 Feb;49(1-2):73-82. Epub 2010 Oct 8.
    [ PubMed Abstract ]
  • Parnes, HL. Prostate Cancer Prevention: Do the 5-ARIs make the grade? Am J Bioeth. 2011 Dec;11(12):30-1.
    [ PubMed Abstract - in process ]
  • Parnes H, House M, Tangrea J. Updates in prostate cancer prevention. Emerging Cancer Therapeutics. 2011, in review.
  • Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Thompson IM, Ambrosone CB, Hoque A.  Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. Cancer Causes Control. 2011 Aug;22(8):1121-31.
    [ PubMed Abstract ]
  • Baker SG, Darke AK, Pinsky P, Parnes HL, Kramer BS. Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial. Biostatistics. 2010 Jul;11(3):413-8. Epub 2010 Feb 19.
    [ PubMed Abstract ]
  • Brock KE, Graubard BI, Fraser DR, Weinstein SJ, Stolzenberg-Solomon RZ, Lim U, Tangrea JA, Virtamo J, Ke L, Snyder K, Albanes D. Predictors of vitamin D biochemical status in a large sample of middle-aged male smokers in Finland. Eur J Clin Nutr. 2010 Mar; 64(3): 280-8. Epub 2010 Jan 6.
    [ PubMed Abstract ]
  • Figg WS, Woo S, Zhu W, Chen X, Ajiboye AS, Steinberg SM, Price DK, Wright JJ, Parnes HL, Arlen PM, Gulley JL, Dahut WL . A phase I clinical study of high-dose ketoconazole plus weekly docetaxel in metastatic castration-resistant prostate cancer. J Urol. 2010 Jun;183(6):2219-26.
    [ PubMed Abstract ]
  • Gibson TM, Ferrucci LM, Tangrea JA, Schatzkin A. Epidemiological and clinical studies of nutrition. Semin Oncol. 2010 Jun; 37(3):282-96.
    [ PubMed Abstract ]
  • Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML, Parnes HL, Reichardt JK, Santella RM, Till C, Lippman SM. Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila). 2010 Dec;3(12):1523-33.
    [ PubMed Abstract ]
  • Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen C, Kristal A, Lucia S, Wang Q, Kappil M, Thompson I, Hsing AW, Parnes H, Santella RM. Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa). 2010 Apr;3(4):478-83. Epub 2010 Mar 23.
    [ PubMed Abstract ]
  • Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG. BCAN Think Tank session 3: prevention of bladder cancer.  Urol Oncol. 2010 May-Jun;28(3):338-42.
    [ PubMed Abstract ]
  • Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Apr 20;28(12):2070-6. Epub 2010 Mar 22.
    [ PubMed Abstract ]
  • Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, Pollak M.  Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa). 2010 Mar;3(3):279-89. Epub 2010 Feb 23.
    [ PubMed Abstract ]
  • Parnes HL, House MG, Tangrea JA. Prostate cancer chemoprevention strategies, in Drug Management of Prostate Cancer. Figg et al, Editors. Springer-New York, 2010.
  • Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, Reichardt JK, Hoque A, Tangen CM, Kristal AR, Thompson IM, Figg WD. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the Prostate Cancer Prevention Trial.  J Urol. 2010 Dec;184(6):2297-302. Epub 2010 Oct 16.
    [ PubMed Abstract ]